CNS Involvement Risk Higher in AIDS-Related Lymphomas

Share this content:

the Cancer Therapy Advisor take:

Patients with AIDS-related lymphomas (ARLs) appear to be at a higher risk for central nervous system involvement (CNSi), new data presented at ASCO 2014 suggest. Researchers also found that CNSi at the time of ARL diagnosis does not affect overall survival (OS), but those with CNSi at the time of diagnosis were almost three times as likely to experience CNS relapse during cancer treatment. For the study, they analzyed data from 880 patients with ARL to identify links between CNS relapse and a number of patient characteristics, such a sex, CD4 count, treatment history, and more. Thirteen percent of patients had CNSi, 5.3% of whom experienced CNS relapse at a median of 4.2 months after diagnosis. Median OS was 1.6 months, according to the study results. These findings led the researchers to conclude that better strategies for detecting CNSi are needed to identify patients at risk.

Ibrutinib: Second FDA-Approved Drug with Breakthrough Therapy Designation for MCL
CNS Involvement Risk Higher in AIDS-Related Lymphomas

Patients with AIDS-related lymphomas (ARL) may face an increased risk of centra lnervous system involvement (CNSi) compared to other lymphomas. The effect of CNSi on survival outcomes, however, hasn't been thoroughly examined until now.


Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs